Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients ... Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys. Show more
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm PR Newswire STOCKHOLM, Sept. 16, 2024 STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas...
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.